If you have listened to Oppenheimer's analyst you would be screwed by now and getting worse by the day. Shorting IMGN now is extremely stupid and just makes IMGN price to shoot up more post approval when shorts scramble to cover. Eevery time analysts downgrade IMGN, initially IMGN will go down than move back up. This is whats happening right now.
Totally agree, Insidetrack. Not factored into the price is that IMGN holds not just one or a couple drug candidates, but a Franchise on this targeted antibody technology. When I first took interest many years ago, this technology was an exotic experiment. Now Roche is salivating over all of the billions they will make. The next couple agents from IMGN will be a much better deal for us. I invested initially thinking this technology will save many lives from breast cancer, which unfortunately took my beloved grandmother.
I also think the closer this gets to the feb 26 deadline without an approval, the greater the likelyhood of a broader label. If not for negotiation of a broader label,this would have been approved by now. If it does receive a broader label, it will be interesting to see how the analyst revise their projections and targets.